Highlights Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
0.7727 ^USD	-5.42%		-9.88%	-18.44%

05-09	Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia	23-09-21	MT
Everest Medicines Signs License Deal with Kezar for Anti-Autoimmune Disease Medication	23-09-20	MT
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets	23-09-20	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-14	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Kezar Life Sciences, Inc. Presents Positive Complete Results from the Mission Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis At the American College of Rheumatology Convergence 2022	22-11-14	CI
Earnings Flash (KZR) KEZAR LIFE SCIENCES Posts Q3 Loss $-0.25	22-11-10	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Kezar Life Sciences, Inc. Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting	22-11-03	CI
Kezar Life Sciences Gets US FDA Clearance of Investigational New Drug for Autoimmune Hepatitis	22-10-03	MT
Kezar Life Sciences, Inc. Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis	22-10-03	CI
Earnings Flash (KZR) KEZAR LIFE SCIENCES Reports Q2 Loss $-0.25	22-08-11	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Highlights

Filters